Retrospective, non-interventional, study to assess the risk of relapses following Fingolimod discontinuation and the initiation of a B/T cell-depleting agent in multiple sclerosis patients.
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Alemtuzumab (Primary) ; Cladribine (Primary) ; Fingolimod (Primary) ; Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 11 Mar 2022 New trial record
- 01 Mar 2022 Results published in the Journal of Neurology